Tazemetostat + Prednisolone + Tazemetostat
Phase 1/2Completed 0 watching 0 views this week💤 Quiet
38
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
B-cell Lymphomas (Phase 1)
Conditions
B-cell Lymphomas (Phase 1), Advanced Solid Tumors (Phase 1), Diffuse Large B-cell Lymphoma (Phase 2), Follicular Lymphoma (Phase 2), Transformed Follicular Lymphoma, Primary Mediastinal Large B-Cell Lymphoma
Trial Timeline
Jun 13, 2013 → Nov 2, 2021
NCT ID
NCT01897571About Tazemetostat + Prednisolone + Tazemetostat
Tazemetostat + Prednisolone + Tazemetostat is a phase 1/2 stage product being developed by Ipsen for B-cell Lymphomas (Phase 1). The current trial status is completed. This product is registered under clinical trial identifier NCT01897571. Target conditions include B-cell Lymphomas (Phase 1), Advanced Solid Tumors (Phase 1), Diffuse Large B-cell Lymphoma (Phase 2).
Hype Score Breakdown
Clinical
13
Activity
8
Company
7
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01897571 | Phase 1/2 | Completed |
Competing Products
20 competing products in B-cell Lymphomas (Phase 1)